We have updated forecasts to reflect Summit’s plan to establish a direct sales team in the US for ridinilazole, currently in Phase III for the treatment of C. difficile infection (CDI). As a result, our intrinsic value estimate is upgraded to 66p/share (from 48p), with Summit’s growing portfolio of preclinical, new-mechanism antibiotics providing potentially substantial further upside. We reiterate our positive stance.
07 Jun 2019
Direct US sales strategy drives valuation upgrade
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Direct US sales strategy drives valuation upgrade
Summit Therapeutics Inc (SMMT:NAS) | 0 0 0.0%
- Published:
07 Jun 2019 -
Author:
Jens Lindqvist -
Pages:
3
We have updated forecasts to reflect Summit’s plan to establish a direct sales team in the US for ridinilazole, currently in Phase III for the treatment of C. difficile infection (CDI). As a result, our intrinsic value estimate is upgraded to 66p/share (from 48p), with Summit’s growing portfolio of preclinical, new-mechanism antibiotics providing potentially substantial further upside. We reiterate our positive stance.